[Medroxyprogesterone acetate. Contributive treatment in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency in children]. / L'acétate de médroxyprogestérone. Traitement d'appoint dans l'hyperplasie congénitale des surrénales par déficit en 21 hydroxylase chez l'enfant.
Arch Fr Pediatr
; 42(7): 511-6, 1985.
Article
en Fr
| MEDLINE
| ID: mdl-2935112
ABSTRACT
Among 59 children presenting with congenital adrenal hyperplasia due to 21-hydroxylase deficiency observed between 1976 and 1982, 12 (9 males, 3 females) aged 3 1/2 to 12 years, were treated with medroxyprogesterone acetate (MPA) associated with the usual glucocorticoid and eventually mineralo-corticoid treatment. There were two indications precocious puberty after the onset of the gluco-mineralo-corticoid treatment; Unbalanced biological status with advancement of bone maturation. After the onset of MPA, a decrease in plasma 17-hydroxyprogesterone (17 OHP) and testosterone levels is observed, the bone maturation speed decreases when growth in height continues. MPA may be a contributive treatment for congenital adrenal hyperplasia due to 21-hydroxylase deficiency, permitting restoration of biological balance by restraining adrenal function and improving the final height prognosis.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Esteroide Hidroxilasas
/
Hiperplasia Suprarrenal Congénita
/
Medroxiprogesterona
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
Fr
Revista:
Arch Fr Pediatr
Año:
1985
Tipo del documento:
Article